Diligence memo · auto-generated · as of July 2, 2026
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
NextRNA Therapeutics, Inc. operates in Biotechnology, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
NextRNA Therapeutics, Inc. has raised $23M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2022-01-12.
Most recent recorded round closed around 2022-01-12.
Valuation (modeled)modeled
Provath models NextRNA Therapeutics, Inc. at approximately $481M (range $47M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.87× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 70% of Biotechnology peers (4293 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.